Long-term treatment with responsive brain stimulation in adults with refractory partial seizures

Objective: The long-term efficacy and safety of responsive direct neurostimulation was assessed in adults with medically refractory partial onset seizures. Methods: All participants were treated with a cranially implanted responsive neurostimulator that delivers stimulation to 1 or 2 seizure foci via chronically implanted electrodes when specific electrocorticographic patterns are detected (RNS System). Participants had completed a 2-year primarily open-label safety study (n = 65) or a 2-year randomized blinded controlled safety and efficacy study (n = 191); 230 participants transitioned into an ongoing 7-year study to assess safety and efficacy. Results: The average participant was 34 (±11.4) years old with epilepsy for 19.6 (±11.4) years. The median preimplant frequency of disabling partial or generalized tonic-clonic seizures was 10.2 seizures a month. The median percent seizure reduction in the randomized blinded controlled trial was 44% at 1 year and 53% at 2 years (p < 0.0001, generalized estimating equation) and ranged from 48% to 66% over postimplant years 3 through 6 in the long-term study. Improvements in quality of life were maintained (p < 0.05). The most common serious device-related adverse events over the mean 5.4 years of follow-up were implant site infection (9.0%) involving soft tissue and neurostimulator explantation (4.7%). Conclusions: The RNS System is the first direct brain responsive neurostimulator. Acute and sustained efficacy and safety were demonstrated in adults with medically refractory partial onset seizures arising from 1 or 2 foci over a mean follow-up of 5.4 years. This experience supports the RNS System as a treatment option for refractory partial seizures. Classification of evidence: This study provides Class IV evidence that for adults with medically refractory partial onset seizures, responsive direct cortical stimulation reduces seizures and improves quality of life over a mean follow-up of 5.4 years.

[1]  Felice T. Sun,et al.  Closed-loop Neurostimulation: The Clinical Experience , 2014, Neurotherapeutics.

[2]  G. Worrell,et al.  Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial , 2014, Epilepsia.

[3]  Katherine Nickels,et al.  Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy , 2013, Neurology.

[4]  Michael S. Okun,et al.  The temporal pattern of stimulation may be important to the mechanism of deep brain stimulation , 2013, Experimental Neurology.

[5]  Dominique M. Durand,et al.  Functional disconnection of axonal fibers generated by high frequency stimulation in the hippocampal CA1 region in-vivo , 2013, Brain Research.

[6]  A. Lozano,et al.  Probing and Regulating Dysfunctional Circuits Using Deep Brain Stimulation , 2013, Neuron.

[7]  E. Ben-Menachem,et al.  Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial‐onset seizures: Interim results from phase III, extension study 307 , 2013, Epilepsia.

[8]  Catharyn T. Liverman,et al.  Epilepsy across the spectrum: Promoting health and understanding. A summary of the Institute of Medicine report , 2012, Epilepsy & Behavior.

[9]  P. House.  Responsive cortical stimulation for the treatment of medically intractable partial epilepsy , 2012 .

[10]  Simon Shorvon,et al.  Sudden unexpected death in epilepsy , 2011, The Lancet.

[11]  M. Morrell.  Responsive cortical stimulation for the treatment of medically intractable partial epilepsy , 2011, Neurology.

[12]  P. Frankland,et al.  Stimulation of Entorhinal Cortex Promotes Adult Neurogenesis and Facilitates Spatial Memory , 2011, The Journal of Neuroscience.

[13]  D. Sakas,et al.  Sustained Relief after Discontinuation of DBS for Dystonia: Implications for the Possible Role of Synaptic Plasticity and Cortical Reorganization , 2011, Central European Neurosurgery.

[14]  John S. Duncan,et al.  Selecting patients for epilepsy surgery: Synthesis of data , 2011, Epilepsy & Behavior.

[15]  M. Nei,et al.  Sudden Unexpected Death in Epilepsy , 2010, Current neurology and neuroscience reports.

[16]  Steve S. Chung,et al.  Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy , 2010, Epilepsia.

[17]  M. Brodie,et al.  Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy , 2010 .

[18]  Alicia L. Jensen,et al.  High frequency stimulation can block axonal conduction , 2009, Experimental Neurology.

[19]  A. Aldenkamp,et al.  The impact of side effects on long-term retention in three new antiepileptic drugs , 2009, Seizure.

[20]  F. Gilliam,et al.  Adverse antiepileptic drug effects , 2009, Neurology.

[21]  Ioannis U Isaias,et al.  Deep brain stimulation for primary generalized dystonia: long-term outcomes. , 2009, Archives of neurology.

[22]  Grant D. Huang,et al.  Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. , 2009, JAMA.

[23]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .

[24]  Karen Byth,et al.  Risk factors for complications during intracranial electrode recording in presurgical evaluation of drug resistant partial epilepsy , 2009, Acta Neurochirurgica.

[25]  E. Ben-Menachem,et al.  Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures , 2007, Epilepsia.

[26]  G. Zaccara,et al.  Idiosyncratic Adverse Reactions to Antiepileptic Drugs , 2007, Epilepsia.

[27]  Steve S. Chung,et al.  Comparative retention rates and long-term tolerability of new antiepileptic drugs , 2007, Seizure.

[28]  David F. Smith,et al.  The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[29]  G. Friehs,et al.  Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder , 2006, Neuropsychopharmacology.

[30]  G. Zaccara,et al.  Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long‐term studies? , 2006, Acta neurologica Scandinavica.

[31]  Michael Seidenberg,et al.  Cognitive prognosis in chronic temporal lobe epilepsy , 2006, Annals of neurology.

[32]  Michael S Okun,et al.  Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder , 2006, Neuropsychopharmacology.

[33]  Gregory P. Lee,et al.  Determinants of quality of life in epilepsy , 2004, Epilepsy & Behavior.

[34]  B. Bourgeois,et al.  CME Efficacy and tolerability of the new antiepileptic drugs I : Treatment of new onset epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society , 2004 .

[35]  J. Vitek,et al.  Stimulation of the Subthalamic Nucleus Changes the Firing Pattern of Pallidal Neurons , 2003, The Journal of Neuroscience.

[36]  D. Spencer,et al.  Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons , 2003, Neurology.

[37]  W T Blume,et al.  A randomized, controlled trial of surgery for temporal-lobe epilepsy. , 2001, The New England journal of medicine.

[38]  R. Gilmartin,et al.  Prospective Long‐Term Study of Vagus Nerve Stimulation for the Treatment of Refractory Seizures , 2000, Epilepsia.

[39]  Wade M. Mueller,et al.  Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy , 1999, Neurology.

[40]  N. Leidy,et al.  Seizure frequency and the health-related quality of life of adults with epilepsy , 1999, Neurology.

[41]  M. Saio,et al.  Evidence for the Synthesis of Corticosteroid-Binding Globulin in Human Placenta , 1999, Hormone Research in Paediatrics.

[42]  G. Morris,et al.  Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. , 1999, Neurology.

[43]  B. Uthman,et al.  Vagus nerve stimulation therapy for partial-onset seizures , 1998, Neurology.

[44]  G K Bergey,et al.  Subdural grid implantation for intracranial EEG recording: CT and MR appearance. , 1998, AJNR. American journal of neuroradiology.

[45]  R König,et al.  Surgical and neurological complications in a series of 708 epilepsy surgery procedures. , 1998, Neurosurgery.

[46]  A. Dupont,et al.  U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION , 1996 .

[47]  R. Hays,et al.  Development of the Quality of Life in Epilepsy Inventory , 1995, Epilepsia.

[48]  Lippincott Williams Wilkins,et al.  A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures , 1995, Neurology.

[49]  R. Dasheiff,et al.  Sudden unexpected death in epilepsy: a series from an epilepsy surgery program and speculation on the relationship to sudden cardiac death. , 1991, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.